Ken Griffin Adagio Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	N/A	1,000 Added 76.92%	2,300 $7,000
Q2 2024 Aug 14, 2024	SELL	N/A	-11,700 Reduced 90.0%	1,300 $4,000
Q1 2024 May 15, 2024	SELL	N/A	-33,500 Reduced 72.04%	13,000 $43,000
Q4 2023 Feb 14, 2024	BUY	N/A	46,500 New	46,500 $153,000
Q2 2023 Aug 14, 2023	SELL	N/A	-24,900 Reduced 83.0%	5,100 $16,000
Q1 2023 May 15, 2023	BUY	N/A	23,200 Added 341.18%	30,000 $99,000
Q4 2022 Feb 14, 2023	SELL	$3.08 - $4.05 $43,736 - $57,510	-14,200 Reduced 67.62%	6,800 $22,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $4.83 $227,205 - $369,495	-76,500 Reduced 78.46%	21,000 $66,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.